Radiopharmacology and molecular imaging of PD-L1 expression in cancer
- 64 Downloads
Immunotherapy [(specifically, antibodies blocking programmed death ligand-1 (PD-L1)] is a valuable option in cancer treatment because it leads to durable tumour regression and improves survival in several cancers. Patients with PD-L1 expressing tumours benefit from this therapy, but currently it can only be determined through biopsy, which may be inconclusive or impossible due to lesion location, associated risks, intratumoral and interlesional heterogeneity. Therefore, radio-immune-imaging with a specific radiopharmaceutical is ideally placed to play an important role when performing real-time, in vivo, whole-body and non-invasive PD-L1 expression mapping.
To describe and summarise published scientific data on imaging PD-L1 expression using radiopharmaceuticals and discuss future directions in this research field.
A summary review of the literature was done through PubMed to search papers that described and included radiopharmaceuticals to image PD-L1 expression. Only English papers published until April 2018 that detailed laboratorial and animal procedures were selected.
Eleven pre-clinical papers published between 2015 and 2018 were included. Four studies used anti-PD-L1 radiopharmaceuticals labelled with Indium-111, 4 with Copper-64, 2 with Fluoride-18 and 1 with both Copper-64 and Gallium-68. All of them had identical protocols and showed similar radiopharmaceutical biodistribution. They reported successful anti-PD-L1 labelling, with high tumour–background ratio (mainly when spleen uptake was saturated with unlabelled/cold antibody).
All reported radiopharmaceuticals had high sensitivity and specificity to identify tumours with PD-L1 expression in animal model. Clinical experiments appear to be now justifiable.
KeywordsAnti-PD-L1 Checkpoint inhibitors Immunotherapy Radiopharmacology Molecular imaging Nuclear medicine
SCV: Literature Search and Review; Manuscript Writing, Editing and Content Planning. ASC: Literature Review; Manuscript Writing, Editing and Content Planning. FPO: Literature Review; Manuscript Writing, Editing and Content Planning. NG: Editing and Content Planning. CB: Editing and Content Planning. AP: Editing and Content Planning. DCC: Manuscript Writing, Editing and Content Planning.
S. C. Vaz, A. S. Capacho and D. C. Costa received antibody anti-PDL1 [clone 6E11] through a MTA from Genentech.
Compliance with ethical standards
Conflict of interest
F. P. Oliveira, N. Gil, C. Barros and A. Parreira declare no conflict of interest.
Not applicable. This is a literature review. This article does not contain any studies with human participants or animals performed by any of the authors.
- 1.Chatterjee S, Lesniak WG, Gabrielson M, Lisok A, Wharram B, Sysa-Shah P, Azad BB, Pomper MG, Nimmagadda S (2016) A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget 7(9):10215–10227. https://doi.org/10.18632/oncotarget.7143 CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Zhang T, Xie J, Arai S, Wang L, Shi X, Shi N, Ma F, Chen S, Huang L, Yang L, Ma W, Zhang B, Han W, Xia J, Chen H, Zhang Y (2016) The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget 7(45):73068–73079. https://doi.org/10.18632/oncotarget.12230 CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Huang G, Sun X, Liu D, Zhang Y, Zhang B, Xiao G, Li X, Gao X, Hu C, Wang M, Ren H, Qin S (2017) The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis. Oncotarget 9(3):4239–4248. https://doi.org/10.18632/oncotarget.23279 CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Santarpia M, González-Cao M, Viteri S, Karachaliou N, Altavilla G, Rosell R (2015) Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. Transl Lung Cancer Res 4(6):728–742. https://doi.org/10.3978/j.issn.2218-6751.2015.12.04 CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7529):563–567. https://doi.org/10.1038/nature14011 CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T (2000) Engagement of the Pd-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192(7):1027–1034CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Maute RL, Gordon SR, Mayer AT, McCracken MN, Natarajan A, Ring NG, Kimura R, Tsai JM, Manglik A, Kruse AC, Gambhir SS, Weissman IL, Ring AM (2015) Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci USA 112(47):E6506–E6514. https://doi.org/10.1073/pnas.1519623112 CrossRefPubMedGoogle Scholar
- 14.Josefsson A, Nedrow JR, Park S, Banerjee SR, Rittenbach A, Jammes F, Tsui B, Sgouros G (2016) Imaging, biodistribution, and dosimetry of radionuclide-labeled PD-L1 antibody in an immunocompetent mouse model of breast cancer. Cancer Res 76(2):472–479. https://doi.org/10.1158/0008-5472.CAN-15-2141 CrossRefPubMedGoogle Scholar
- 17.Trotter DEG, Meng X, McQuade P, Rubins D, Klimas M, Zeng Z, Connolly BM, Miller PJ, O’Malley SS, Lin S-A, Getty KL, Fayadat-Dilman L, Liang L, Wahlberg E, Widmark O, Ekblad C, Frejd FY, Hostetler ED, Evelhoch JL (2017) In vivo imaging of the programmed death ligand 1 by 18F PET. J Nucl Med 58(11):1852–1857. https://doi.org/10.2967/jnumed.117.191718 CrossRefGoogle Scholar
- 18.Cole EL, Kim J, Donnelly DJ, Smith RA, Cohen D, Lafont V, Morin PE, Huang RY-C, Chow PL, Hayes W Jr (2017) Radiosynthesis and preclinical PET evaluation of 89Zr-nivolumab (BMS-936558) in healthy non-human primates. Bioorg Med Chem 25(20):5407–5414. https://doi.org/10.1016/j.bmc.2017.07.066 CrossRefPubMedGoogle Scholar
- 19.England CG, Ehlerding EB, Hernandez R, Rekoske BT, Graves SA, Sun H, Liu G, McNeel DG, Barnhart TE, Cai W (2017) Preclinical pharmacokinetics and biodistribution studies of 89Zr-labeled Pembrolizumab. J Nucl Med 58(1):162–168. https://doi.org/10.2967/jnumed.116.177857 CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Gong J, Chehrazi-Raffle A, Reddi S, Salgia R (2018) Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer 6(1):8. https://doi.org/10.1186/s40425-018-0316-z CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455–2465. https://doi.org/10.1056/NEJMoa1200694 CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, S-l Teng, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558. https://doi.org/10.1038/nature13904 CrossRefGoogle Scholar
- 25.Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, Lizée G, Murphy GF, Hwu P, Flaherty KT, Fisher DE, Wargo JA (2013) BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 19(5):1225–1231. https://doi.org/10.1158/1078-0432.ccr-12-1630 CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Aguiar JPN, Perry LA, Penny-Dimri J, Babiker H, Tadokoro H, de Mello RA, Lopes JGL (2017) The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC. Ann Oncol 28(9):2256–2263. https://doi.org/10.1093/annonc/mdx305 CrossRefPubMedGoogle Scholar
- 29.Donnelly DJ, Smith RA, Morin P, Lipovšek D, Gokemeijer J, Cohen D, Lafont V, Tran T, Cole EL, Wright M, Kim J, Pena A, Kukral D, Dischino DD, Chow P, Gan J, Adelakun O, Wang X-T, Cao K, Leung D, Bonacorsi SJ, Hayes W (2018) Synthesis and biologic evaluation of a novel 18F-labeled adnectin as a PET radioligand for imaging PD-L1 expression. J Nucl Med 59(3):529–535. https://doi.org/10.2967/jnumed.117.199596 CrossRefPubMedGoogle Scholar
- 30.Nedrow JR, Josefsson A, Park S, Ranka S, Roy S, Sgouros G (2017) Imaging of programmed cell death ligand 1: impact of protein concentration on distribution of anti-PD-L1 SPECT agents in an immunocompetent murine model of melanoma. J Nucl Med 58(10):1560–1566. https://doi.org/10.2967/jnumed.117.193268 CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Truillet C, Oh HLJ, Yeo SP, Lee C-Y, Huynh LT, Wei J, Parker MFL, Blakely C, Sevillano N, Wang Y-H, Shen YS, Olivas V, Jami KM, Moroz A, Jego B, Jaumain E, Fong L, Craik CS, Chang AJ, Bivona TG, Wang C-I, Evans MJ (2018) Imaging PD-L1 expression with immunoPET. Bioconjug Chem 29(1):96–103. https://doi.org/10.1021/acs.bioconjchem.7b00631 CrossRefPubMedGoogle Scholar
- 32.Chatterjee S, Lesniak WG, Miller MS, Lisok A, Sikorska E, Wharram B, Kumar D, Gabrielson M, Pomper MG, Gabelli SB, Nimmagadda S (2017) Rapid PD-L1 detection in tumors with PET using a highly specific peptide. Biochem Biophys Res Commun 483(1):258–263. https://doi.org/10.1016/j.bbrc.2016.12.156 CrossRefPubMedGoogle Scholar
- 33.Niemeijer A-LN, Smit EF, GaMSv Dongen, Windhorst AD, Huisman MC, Hendrikse NH, Leung DK, Smith RA, Hayes W, Velasquez LM, Bonacorsi SJ, Donnelly DJ, Morin PE, Thunnissen E, Poot AJ, Vugts DJ, Langen JD (2017) Whole body PD-1 and PD-L1 PET with 89Zr-nivolumab and 18F-BMS-986192 in pts with NSCLC. J Clin Oncol 35(15_suppl):e20047. https://doi.org/10.1200/jco.2017.35.15_suppl.e20047 CrossRefGoogle Scholar
- 35.Josefsson A, Nedrow J, Park S, Ranka S, Sgouros G (2016) Dosimetric analysis of Actinium-225 labeled anti-PD-L1 alpha particle radioimmunotherapy of melanoma cancer in an immunocompetent mouse model. J Nucl Med 57(Supplement 2):635Google Scholar